BioNTech will close sites in Germany and Singapore after failing to find buyers following its move away from pandemic-era manufacturing. The affected locations are in Idar-Oberstein, Marburg, Tuebingen and Singapore, and the restructuring covers up to 1,860 jobs as COVID-19 vaccine production transfers to partner Pfizer. The company said it agreed with the works council on socially responsible measures and additional redundancy terms. BioNTech also said in March that its two co-founders would leave by the end of this year to start a new venture.